Biochemistry, Genetics and Molecular Biology
Circulating Tumor DNA
91%
Epidermal Growth Factor Receptor
76%
P53
61%
KRAS
45%
Cancer Mortality
45%
Smoking
45%
Chromosome Instability
45%
Exome Sequencing
38%
RNA Sequence
34%
Loss of Heterozygosity
30%
Evolutionary Genomics
30%
Gene Mutation
30%
Immune Response
30%
Clonal Evolution
30%
Cancer Cell
30%
SMARCA4
30%
Chromosome 3q
30%
Chromosome 3p
30%
Disease Free Survival
30%
Body Composition
30%
Genomics
30%
Body Weight
22%
Gender Bias
20%
ROS1
15%
Oncogene
15%
Mutagenesis
15%
Isoform
15%
GDF15
15%
Imatinib
15%
Drive
15%
Anticancer
15%
Mediator
15%
Tumor Gene
15%
Phylogeny
15%
Skeletal Muscle
15%
Tyrosine Kinase
15%
Receptor Tyrosine Kinase
15%
Transcriptomics
9%
DNA Analysis
8%
Biological Phenomena and Functions Concerning the Entire Organism
7%
Body Mass
7%
Computer Assisted Tomography
7%
Matrix Metalloproteinase
7%
Proteomics
7%
Cancer Specific Survival
7%
Overall Survival
7%
Drug Resistance
7%
Genome Instability
7%
Mouse Model
7%
Medicine and Dentistry
Metastatic Carcinoma
100%
Circulating Tumor DNA
91%
Neoplasm
90%
Malignant Neoplasm
70%
Primary Tumor
55%
Immunotherapy
47%
Non Small Cell Lung Cancer
39%
Cancer Types
38%
Lung Cancer
33%
Metastatic Cancer
30%
Metastatic Melanoma
30%
Immunocompetent Cell
30%
Colorectal Cancer
30%
Recurrent Disease
15%
Cancer Mortality
11%
Cancer Cell
11%
Gender Bias
10%
Metastatic Bladder Cancer
10%
Hazard Ratio
10%
DNA Determination
8%
Immune Response
7%
The Cancer Genome Atlas
7%
Protein P53
7%
Transcriptomics
7%
Epidermal Growth Factor Receptor
6%
Lung Adenocarcinoma
5%
Smoking
5%
Meta-Analysis
5%
Adaptive Response
5%
Immunity
5%
Immune Cell Infiltration
5%
Cancer Therapy
5%
Absence
5%
Overall Survival
5%
Lymphadenopathy
5%
Disease Exacerbation
5%
Metastasis Potential
5%
Keyphrases
Chromosome Doubling
30%
Mixed Response
30%
Multiregion
30%
DNA Release
30%
Intra-patient
15%
EGFR Tyrosine Kinase
15%
Tyrosine Kinase Inhibition
15%
Isogenic
7%
Co-mutation
7%
TP53 Co-mutation
7%
Copy number Aberrations
7%
Genome Copy number
7%
P53 mutant
7%
Mixed Tumor
7%
Inhibition Resistance
7%
Advanced Lung Adenocarcinoma
7%
Mutant Model
7%
Copy number Gain
7%